{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >3xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >5xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >10xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >20xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"Total Bilirubin > 2xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >3xULN with total Bilirubin > 2xULN within 1 day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}],"title":"ALT or AST >3xULN with total Bilirubin >2xULN within 30 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"groups":[{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1\n\nPomalidomide:\n\n4 mg po daily (Days 1-21) of each 28-day cycle\n\nDexamethasone:\n\nWeeks without daratumumab dosing 40 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects 75 years old 20 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects \\> 75 years old","id":"OG000","title":"Nivolumab + Daratumumab_Cohort A1"},{"description":"ND-Pd Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG001","title":"Nivolumab + Daratumumab_Cohort A2"},{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG002","title":"Nivolumab + Daratumumab_Cohort B1"},{"description":"D Monotherapy Regimen\n\nEach cycle is 28 days\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG003","title":"Nivolumab + Daratumumab_Cohort B2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in the nivo dara cohort","reportingStatus":"POSTED","timeFrame":"approximately up to 4 years","title":"Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade in the Nivolumab + Daratumumab Cohort - Liver","type":"PRIMARY","unitOfMeasure":"Participants"}